Tesamorelin in Mexico: GHRH (1-44) analog approved by the FDA

EXOMA Scientific Team · Publicado el 24 de mayo de 2026 · Actualizado el 18 de septiembre de 2026

Tesamorelin is a stabilized analog of GHRH (1-44) with a trans-3-hexenoyl group at the N-terminal position. The only GHRH analog approved by the FDA (HIV lipodystrophy).

Executive summary

Tesamorelin (Tesamorelin, CAS 901758-09-6, molecular formula C221H366N72O67S, molecular weight 5135.81 g/mol) is the object of growing interest in preclinical research for being the only GHRH analog with FDA approval, indicated for the reduction of abdominal fat in HIV-associated lipodystrophy. This technical guide brings together molecular characterization, mechanism of action, bibliographic evidence with DOI/PubMed, and handling considerations for research use only.

Regulatory notice. This material is exclusively for in vitro and preclinical research use. It does not constitute a clinical or therapeutic recommendation.

What is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing factor (hGRF, GHRH 1-44) with the addition of a trans-3-hexenoyl group attached to the N-terminal end. This modification protects the peptide against degradation by DPP-IV, prolonging its plasma half-life compared to native GHRH.

Key molecular data

Mechanism of action

Its mechanism is selective agonism of the GHRH-R receptor in pituitary somatotrophs, stimulating the pulsatile release of endogenous GH with preservation of the hypothalamic-pituitary axis. Tesamorelin has FDA approval for the reduction of abdominal fat in patients with HIV infection-associated lipodystrophy.

The mechanistic characterization available in indexed literature (PubMed, Web of Science) makes it possible to categorize Tesamorelin as an object of research of high interest in its category. The most highly cited publications are reproduced in the section Bibliographic evidence below.

Documented lines of research

The available preclinical literature addresses mainly:

1. Pharmacokinetic characterization: in vivo studies in murine and porcine models on absorption, distribution, metabolism, and excretion of the analog.
2. Receptor mechanisms: competitive binding assays with radioligands to map affinity and selectivity for target receptors.
3. Animal efficacy models: preclinical assays on the phenotypic effect attributable to the peptide in models of the pathology under study.
4. In vitro stability and formulation: evaluation of the chemical and biological stability of the peptide under different storage and reconstitution conditions.

For an up-to-date systematic review, the researcher is advised to consult the PubMed, Google Scholar and Web of Science databases using the terms Tesamorelina and Tesamorelin.

Bibliographic evidence

• Falutz J et al., 2007 — N Engl J Med. Tesamorelin reduced abdominal visceral fat in patients with HIV lipodystrophy in a phase III study. DOI: 10.1056/NEJMoa072375
• Stanley TL et al., 2014 — JAMA. Tesamorelin and reduction of hepatic steatosis in patients with HIV. DOI: 10.1001/jama.2014.8334

Handling, reconstitution, and storage

Receipt and verification. Each lyophilized vial of Tesamorelin is shipped with its corresponding certificate of analysis (COA) issued by Chromasys, which includes identity by mass spectrometry, purity by reverse-phase HPLC, peptide content by amino acid analysis, residual acetate/TFA, residual water by Karl Fischer and endotoxins by LAL.

Standard reconstitution (research protocol). The standard procedure for sterile reconstitution is as follows:

1. Disinfect with isopropyl alcohol the rubber stoppers of the lyophilized Tesamorelin vial and of the vial of bacteriostatic water (BAC).
2. Aspirar el volumen calculado de BAC con jeringa de insulina estéril (consultar la EXOMA reconstitution calculator).
3. Inject the solvent slowly, resting the needle against the inner wall of the vial — never directly onto the lyophilized powder, to avoid aggregation and denaturation.
4. Gently roll the vial between your fingers until a clear solution is obtained. Never shake.
5. Store the reconstituted vial refrigerated (2–8 °C) protected from light. Avoid freeze-thaw cycles.

Storage of the lyophilizate. Refrigerated at 2–8 °C protected from light until the retest date indicated in the batch's COA.

Products available at EXOMA

• `/producto/tesamorelin`
• `/producto/tesamorelin`

All presentations are shipped with a batch COA and meet the reverse-phase HPLC purity standard. The larger-mass presentation usually offers the lowest cost per milligram.

Logistics and delivery

• Coverage. All of the Mexican Republic via courier with tracking number (AfterShip).
• Transit time. 1-4 business days depending on the region from payment confirmation.
• Shipping cost. $200 MXN de tarifa nacional única; envío gratuito en pedidos desde $2,000 MXN.
• Processing cutoff. Pedidos confirmados antes de las 16:30 (4:30 PM) hora del centro de México de lunes a viernes salen el mismo día hábil.

Additional resources

• Scientific hub: /producto/tesamorelin — variants, comparisons, studies, and full FAQ.
• Compendium: /compendio/tesamorelin — technical sheet with sequence and molecular references.
• Reconstitution calculator: /calculadora.
• Storage guide: /guia-conservacion.

This guide is educational content aimed at researchers. The information does not constitute medical advice or diagnosis. All data are reproduced for technical purposes and to support research-material procurement decisions. Bibliographic references are available on PubMed/DOI for independent verification.

References

Material for research use only. The following primary sources support the scientific claims of this article:

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID 18057338.
2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID 20554713.